Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186546 · ClinicalTrials.gov registry record
Zephyr Valve Registry (ZEVR)
A clinical trial of Emphysema, sponsored by Pulmonx Corporation.
- Active
- Registry status
- 150
- Enrollment target
- 11
- Study locations
NCT04186546: Active study of Emphysema, sponsored by Pulmonx Corporation.
NCT04186546 is a study of Emphysema that is active but no longer recruiting, run by Pulmonx Corporation. The registered enrollment target is 150 participants, below the 3,797-participant average among 25 other Emphysema trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04186546, a study of Emphysema, is active but no longer recruiting, sponsored by Pulmonx Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
Primary Outcome
The percentage of study participants undergoing the Zephyr Valve Procedure who develop a pneumothorax from the date of the procedure to 45-day post intervention.
Conditions Studied
Interventions
- DEVICE Zephyr Valve Procedure
Study Locations (11)
Pennsylvania
- The Lung Center - DuBois
- University of Pennsylvania - Philadelphia
- Temple University Hospital - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
Illinois
- University of Chicago - Chicago
- Northwestern Medicine - Winfield
Alabama
- University of Alabama at Birmingham - Birmingham
Michigan
- Henry Ford Hospital - Detroit
Texas
- Houston Methodist - Houston
Virginia
- Inova Health - Fairfax
Wisconsin
- Froedtert Memorial-Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT04186546 still lists
NCT04186546 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,797-participant average among 25 other Emphysema trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 1 intervention - of which Zephyr Valve Procedure is the first listed.
NCT04186546 lists 11 locations in 7 states (Pennsylvania, Illinois, Alabama).
Frequently Asked Questions
What is clinical trial NCT04186546 about?
NCT04186546 is a clinical study titled "Zephyr Valve Registry (ZEVR)". The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
What is the current status of trial NCT04186546?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2019-11-25. Estimated completion is 2026-12-31.
What conditions does trial NCT04186546 study?
This clinical trial studies the following conditions: Emphysema.
What interventions are being tested in trial NCT04186546?
The interventions under investigation include: Zephyr Valve Procedure (DEVICE).
Who is sponsoring clinical trial NCT04186546?
This trial is sponsored by Pulmonx Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04186546 being conducted?
This trial has 11 study locations across Alabama, Illinois, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04186546's enrollment target sits among peer trials
150 12th of 25 higher than 13 of 25 other Emphysema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Emphysema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COPD Patient-Powered Research Network
RECRUITING
-
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
RECRUITING · NA
-
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI